Scholarlink

<p>Interferon regulatory factor 7 (<i>IRF7</i>) regulates immune responses but its prognostic role in kidney renal clear cell carcinoma (KIRC) is undefined. Given KIRC’s high incidence (70–80% of renal cancers) and limited late-stage therapies, we assessed <i>IRF7</i>’s clinical utility through multi-omics analysis. Using TCGA, GTEx, CPTAC, and tissue microarrays, we analyzed <i>IRF7</i> in 33 cancers. Assessments included survival (DSS/PFI/OS), functional enrichment (GSEA), drug sensitivity (GSCA), single-cell functional state analysis using the CancerSEA database, and prognostic nomogram construction. <i>IRF7</i> was dysregulated in 22 cancers (KIRC: <i>p</i> &lt; 0.001), with elevated expression correlating to poor survival (<i>p</i> &lt; 0.01). It associated with immune checkpoints, epigenetic modifiers, T-cell activity, and methylation. Functional analyses implicated <i>IRF7</i> in fatty acid metabolism, oxidative phosphorylation, and drug sensitivity. A KIRC-specific nomogram predicted OS with high accuracy. Tissue microarrays confirmed <i>IRF7</i> overexpression in KIRC versus normal tissues (<i>p</i> &lt; 0.001), linked to reduced survival. <i>IRF7</i> is a novel prognostic biomarker in KIRC, influencing tumor immunity and therapy response. Its integration into clinical nomograms could guide precision immunotherapy strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

IRF7 is a novel prognostic biomarker in kidney renal clear cell carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月17日

查看全文
  • Shuangshuang Fu,
  • Wenhui Zhou,
  • Wei Yin,
  • Ying Chen,
  • Liyuan Cao,
  • Yusa Chen,
  • Zheng Xiao

摘要

Interferon regulatory factor 7 (IRF7) regulates immune responses but its prognostic role in kidney renal clear cell carcinoma (KIRC) is undefined. Given KIRC’s high incidence (70–80% of renal cancers) and limited late-stage therapies, we assessed IRF7’s clinical utility through multi-omics analysis. Using TCGA, GTEx, CPTAC, and tissue microarrays, we analyzed IRF7 in 33 cancers. Assessments included survival (DSS/PFI/OS), functional enrichment (GSEA), drug sensitivity (GSCA), single-cell functional state analysis using the CancerSEA database, and prognostic nomogram construction. IRF7 was dysregulated in 22 cancers (KIRC: p < 0.001), with elevated expression correlating to poor survival (p < 0.01). It associated with immune checkpoints, epigenetic modifiers, T-cell activity, and methylation. Functional analyses implicated IRF7 in fatty acid metabolism, oxidative phosphorylation, and drug sensitivity. A KIRC-specific nomogram predicted OS with high accuracy. Tissue microarrays confirmed IRF7 overexpression in KIRC versus normal tissues (p < 0.001), linked to reduced survival. IRF7 is a novel prognostic biomarker in KIRC, influencing tumor immunity and therapy response. Its integration into clinical nomograms could guide precision immunotherapy strategies.